Tonix Pharmaceutical

Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia

Email Print Friendly Share
September 03, 2020 09:00 ET | Source: Tonix Pharmaceuticals Holding Corp.


Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020
Positive Outcomes in Both Trials Would Support Submission of NDA in Second Half 2022
 
Southern Research and Tonix make headway in Covid-19 vaccine
Tonix up 7%
 

Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia​

 
Tonix Pharmaceuticals Holding Corp. ( NASDAQ: TNXP ) El Dr. Seth Lederman le dice a Proactive que la compañía biofarmacéutica en etapa clínica ha formado un acuerdo de licencia exclusivo para desarrollar un posible tratamiento para el coronavirus, TNX-3500, de OyaGen, Inc., una compañía de investigación de biotecnología preclínica. El Dr. Lederman dice que el TNX-3500 es '65 veces más potente 'que el Remdesivir de Gilead, in vitro, para inhibir el coronavirus. Agrega que el grupo está muy emocionado de trasladar TNX-3500 a estudios con animales y, posteriormente, a pruebas clínicas en humanos.

 

Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting​

Confirmatory Phase 3 Study, RALLY, Ongoing with Interim Analysis Expected in Third Quarter 2021​

June 03, 2021 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.
 
Top